Joseph Krakowiak
Family Medicine · Augusta, GANPI 1518316041
Payments from drug & device makers
Across 95 payments — averaging $20.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Viiv Healthcare Company$346
- Merck$212
- AstraZeneca$192
- AbbVie$143
- Novo Nordisk$138
- Lilly USA, LLC$122
- plus $792 from 19 others
What the payments were for
- Food & beverage$1,945100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Viiv Healthcare Company | 15 | $346 |
| Merck | 9 | $212 |
| AstraZeneca | 10 | $192 |
| AbbVie | 6 | $143 |
| Novo Nordisk | 8 | $138 |
| Lilly USA, LLC | 6 | $122 |
| Exact Sciences | 6 | $103 |
| Theratechnologies Inc. | 3 | $102 |
| Bayer | 4 | $80 |
| Xeris Pharmaceuticals, Inc. | 3 | $60 |
| GSK | 3 | $54 |
| Gilead | 3 | $49 |
| Novartis | 2 | $42 |
| Amgen | 3 | $42 |
| Dexcom, Inc. | 2 | $34 |
| Otsuka America Pharmaceutical, Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 1 | $31 |
| Pfizer | 2 | $26 |
| Organon | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $21 |
| Johnson & Johnson | 1 | $21 |
| Abbott | 1 | $19 |
| Alkermes, Inc. | 1 | $18 |
| Phathom Pharmaceuticals, Inc. | 1 | $16 |
| Corcept Therapeutics | 1 | $15 |
How this compares
$1,945 in reported general payments places this provider in the 70th percentile of 3,111 family medicine providers in Georgia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 27 | $29,961 |
| MounjaroTirzepatide | 22 | $26,567 |
| EliquisApixaban | 26 | $22,788 |
| TrulicityDulaglutide | 15 | $17,099 |
| Spiriva HandihalerTiotropium Bromide | 14 | $11,220 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 45 | $2,064 |
| Pregabalin | 20 | $1,601 |
| Atorvastatin Calcium | 103 | $1,259 |
| Omeprazole | 59 | $733 |
| Carvedilol | 56 | $721 |
| Trazodone Hcl | 53 | $619 |
| Rosuvastatin Calcium | 24 | $460 |
| Lisinopril | 50 | $451 |
| Famotidine | 27 | $446 |
| Amlodipine Besylate | 78 | $426 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $122 | $43,66637 claims |
| Novo NordiskOzempic | $138 | $29,96127 claims |
| PfizerEliquis | $26 | $22,78826 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,111 family medicine providers in Georgia.
Other family medicine in Augusta
- Daron FerrisAugusta$186K
- David KriegelAugusta$36K
- Joseph SurberColumbus$16.6M
- Angela RitterGainesville$15.8M
- Jeffrey KingsleyColumbus$8.1M
- Christopher OldfieldSavannah$6.4M
- Darrell MurrayAtlanta$3.9M
- Ben ThomasAtlanta$3.2M
- Debbie HaginsSavannah$2.1M
- Aziz PiraniLilburn$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.